UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco, and co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the management of first relapse in patients with multiple myeloma.

Hope S. Rugo, MD, discusses the impact of margetuximab in patients with HER2-positive metastatic breast cancer who have an F allele versus V allele.

Nina Shah, MD, discusses the utility of minimal residual disease in frontline multiple myeloma.

Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment considerations in myelofibrosis.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Hope S. Rugo, MD, discusses results of a randomized phase III trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Thomas G. Martin, MD, discusses the impact of subcutaneous administration of daratumumab on patients with early relapse multiple myeloma.

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the utility of venetoclax in acute myeloid leukemia.

Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.

Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Margetuximab in combination with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer.

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses investigational agents in chronic myeloid leukemia (CML).

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the elements of the I-SPY 2 trial in breast cancer.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the results of the phase III ECHELON-1 trial in Hodgkin lymphoma.

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses novel therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.